Osteoporosis: Evaluation and treatment

Current Women's Health Reports

Volumn 3, Issue 5, 2003, Pages 418-424

  Bajaj, Sonia ^a   Saag, Kenneth G ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CYCLOSPORIN; ESTROGEN; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; PAMIDRONIC ACID; PARATHYROID HORMONE; PLACEBO; PREDNISONE; PROGESTERONE; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TACROLIMUS; THYROID HORMONE; VITAMIN D;

BONE STRENGTH; BRACE; BREAST CANCER; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIAGNOSTIC PROCEDURE; DIARRHEA; DISEASE PREDISPOSITION; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG POTENTIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ESOPHAGITIS; EVIDENCE BASED MEDICINE; FEMALE; FRACTURE; GASTROINTESTINAL SYMPTOM; HEADACHE; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPERCALCEMIA; KINESIOTHERAPY; LEG CRAMP; MALE; NAUSEA; ORTHOPEDIC SURGERY; OSTEOLYSIS; OSTEOPOROSIS; PERCUTANEOUS VERTEBROPLASTY; POSTMENOPAUSE; PROTECTIVE EQUIPMENT; PUBLIC HEALTH; REVIEW; RHINITIS; STROKE; TREATMENT PLANNING; UPPER GASTROINTESTINAL TRACT; UROLITHIASIS; VENOUS THROMBOEMBOLISM; AGED; ESTROGEN THERAPY; EXERCISE; METHODOLOGY; MIDDLE AGED; PATHOLOGIC FRACTURE; PATIENT EDUCATION; POSTMENOPAUSE OSTEOPOROSIS; WOMEN'S HEALTH;

AGED; CALCITONIN; DIPHOSPHONATES; ESTROGEN REPLACEMENT THERAPY; EXERCISE; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; PATIENT EDUCATION; RALOXIFENE; VITAMIN D; WOMEN'S HEALTH;

EID: 1542673146     PISSN: 15345874     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. National Institutes of Health: Osteoporosis Prevention, Diagnosis, and Therapy. National Institutes of Health Consensus Development Conference Statement, March 2001. Baltimore, MD: National Institute of Health, 2001, 17:1-45.
2. Melton LJ III, Chrischilles EA, Cooper C, et al.: Perspective: How many women have osteoporosis? J Bone Miner Res 1992, 7:1005-1010.
3. Chrischilles EA, Butler CD, Davis CS, Wallace RB: A model of lifetime osteoporosis impact. Arch Intern Med 1991, 151:2026-2032.
4. Kanis JA, Melton LJ 3rd, Christiansen C, et al.: The diagnosis of osteoporosis. J Bone Miner Res 1994, 9:1137-1141.
5. World Health Organization: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994, 843:1-129.
6. Krall EA, Dawson-Hughes B: Heritable and life-style determinants of bone mineral density. J Bone Miner Res 1993, 8:1-9.
7. Cummings SR, Nevitt MC, Browner WS, et al.: Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995, 332:767-773.
8. Fox KM, Cummings SR, Williams E, Stone K: Femoral neck and intertrochanteric fractures have different risk factors: a prospective study. Osteoporos Int 2000, 11:1018-1023.
9. Cummings SR, Melton LJ: Epidemiology and outcomes of osteoporotic fractures. Lancet 2002, 359:1761-1767.
10. Adams JS, Lee G: Gains in bone mineral density with resolution of vitamin D intoxication. Ann Intern Med 1997, 127:203-206.
11. Michnovicz JJ, Hershcopf RJ, Naganuma H, et al.: Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. N Engl J Med 1986, 315:1305-1309.
12. Diamond T, Stiel D, Lunzer M, et al.: Ethanol reduces bone formation and may cause osteoporosis. Am J Med 1989, 86:282-288.
13. Cummings SR, Black DM, Nevitt MC, et al.: Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 1993, 341:72-75.
14. Wasnich RD, Davis JW, Ross PD: Spine fracture risk is predicted by non-spine fractures. Osteoporos Int 1994, 4:1-5.
15. Davis JW, Grove JS, Wasnich RD, Ross PD: Spatial relationships between prevalent and incident spine fractures. Bone 1999, 24:261-264.
16. Klotzbuecher CM, Ross PD, Landsman PB, et al.: Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000, 15:721-739.
17. Ross PD, Davis JW, Epstein RS, Wasnich RD: Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991, 114:919-923.
18. Tromp AM, Smit JH, Deeg DJ, et al.: Predictors for falls and fractures in the Longitudinal Aging Study Amsterdam. J Bone Miner Res 1998, 13:1932-1939.
19. Adachi JD, Olszynski WP, Hanley DA, et al.: Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum 2000, 29:228-251.
20. Saag KG: Glucocorticoid-induced osteoporosis. Endocrinol Metab Clin North Am 2003, 32:135-157.
21. Van Staa TP, Leufkens HG, Abenhaim L, et al.: Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000, 15:993-1000.
22. National Osteoporosis Foundation: Physicians Guide to Prevention and Treatment of Osteoporosis. Washington, D.C: National Osteoporosis Foundation, 1998.
23. Reid JR, Ames RW, Evans MC, et al.: Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med 1995, 98:331-335.
24. Cumming RG, Nevitt MC: Calcium for prevention of osteoporotic fractures in postmenopausal women. J Bone Miner Res 1997, 2:1321-1329.
25. Ott SM, Chesnut CH 3rd: Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Intern Med 1989, 10:267-274.
26. Gallagher JC, Goldgar D: Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. Ann Intern Med 1990, 113:649-655.
27. Chapuy MC, Arlot ME, Duboeuf F, et al.: Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992, 327:1637-1642.
28. Nieves JW, Komar L, Cosman F, Lindsay R: Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis. Am J Clin Nutr 1998, 67:18-24.
29. NIH Consensus Development Conference: Optimal calcium intake. JAMA 1994, 272:1942-1948.
30. Institute of Medicine: Dietary Reference Intakes: Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. New York: Academy Press, 1997.
31. Manolagas SC, Jilka RL: Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995, 332:305-311.
32. The Writing Group for the PEPI: Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996, 276:1389-1396.
33. Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002, 288:321-333.
34. Ettinger B, Black DM, Mitlak BH, et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999, 282:637-645.
35. Chesnut CH 3rd, Silverman S, Andriano K, et al.: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures study. PROOF Study Group. Am J Med 2000, 109:267-276.
36. Lyritis GP, Paspati I, Karachalios T et al.: Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures: a double-blind, placebo-controlled clinical study. Acta Orthop Scand Suppl 1997, 275:112-114.
37. Russell RG, Rogers MJ, Frith JC, et al.: The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res 1999, 14(Suppl2):53-65.
38. Liberman UA, Weiss SR, Broll J, et al.: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995, 333:1437-1443.
39. Black DM, Cummings SR, Karpf DB, et al.: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348:1535-1541.
40. Schnitzer T, Bone HG, Crepaldi G, et al.: Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000, 12:1-12.
41. Harris ST, Watts NB, Genant HK, et al.: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999, 282:1344-1352.
42. Reginster J, Minne HW, Sorensen OH, et al.: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000, 11:83-91.
43. McClung MR, Geusens P, Miller PD, et al.: Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001, 344:333-340.
44. Valkema R, Vismans FJ, Papapoulos SE, et al.: Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner 1989, 5:183-192.
45. Neer RM, Arnaud CD, Zanchetta JR, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
46. Lindsay R, Nieves J, Formica C, et al.: Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997, 350:550-555.
47. Grados F, Depriester C, Cayrolle G, et al.: Long-term observations of vertebral osteoporotic fractures treated by percutaneous vertebroplasty. Rheumatology 2000, 39:1410-1414.
48. Lieberman IH, Dudeney S, Reinhardt MK, Bell G: Initial outcome and efficacy of "kyphoplasty" in the treatment of painful osteoporotic vertebral compression fractures. Spine 2001, 26:1631-1638.
49. Wong AM, Lin YC, Chou SW, et al.: Coordination exercise and postural stability in elderly people: effect of Tai Chi Chuan. Arch Phys Med Rehabil 2001, 82:608-612.
50. Heinonen A, Kannus P, Sievanen H, et al.: Randomised controlled trial of effect of high-impact exercise on selected risk factors for osteoporotic fractures. Lancet 1996, 348:1343-1347.
51. Kannus P, Parkkari J, Niemi S, et al.: Prevention of hip fracture in elderly people with use of a hip protector. N Engl J Med 2000, 343:1506-1513.